Awaiting development: Guidance and quality standards

Showing 101 to 110 of 280

Guidance and quality standards awaiting development
Title	Type
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312	Technology appraisal guidance
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [TS ID 12050]	Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]	Technology appraisal guidance
Govorestat for treating classic galactosemia in people 2 to 65 years TS ID 12071	Technology appraisal guidance
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]	Technology appraisal guidance
Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]	Technology appraisal guidance
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]	Technology appraisal guidance
Iclepertin for treating cognitive impairment associated with schizophrenia ID6483	Technology appraisal guidance
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies ID 6491	Technology appraisal guidance
Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor TS ID 8376	Technology appraisal guidance